In 2014, Kochenderfer et al. [9] published the first report on successful treatment of diffuse large B-cell lymphoma (DLBCL), and demonstrated the feasibility and validity of anti-CD19 CAR T cells treating chemotherapy-refractory B-cell malignancies. Here, CD19 is linked to diffuse large B-cell lymphoma.